$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000162828019010465 Filed on August 08, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$2.201M	$1.400M	$4.785M
YoY Change	-45.98%	-70.74%
Cost Of Revenue	$132.4K	-$1.497M	$1.423M
YoY Change	-95.75%	-205.18%
Gross Profit	$2.069M	$2.897M	$3.362M
YoY Change	114.72%	-13.85%
Gross Profit Margin	93.99%	206.91%	70.26%
Selling, General & Admin	$2.852M	$2.666M	$5.084M
YoY Change	-32.01%	-47.55%	253.26%
% of Gross Profit	137.87%	92.05%	151.21%
Research & Development	$1.743M	$3.713M	$1.083M
YoY Change	66.38%	242.9%	119.33%
% of Gross Profit	84.27%	128.17%	32.2%
Depreciation & Amortization	$1.070M	$1.100M	$1.240M
YoY Change	0.0%	-11.29%
% of Gross Profit	51.72%	37.97%	36.88%
Operating Expenses	$9.329M	$10.43M	$10.54M
YoY Change	-67.14%	-1.07%	445.21%
Operating Profit	-$2.862M	-$2.548M	-$5.753M
YoY Change	-88.23%	-55.71%	224.09%
Interest Expense	-$205.9K	$38.41K	-$242.4K
YoY Change	-12.31%	-115.85%	845.76%
% of Operating Profit
Other Income/Expense, Net	$52.71K	$57.32K	-$238.5K
YoY Change	-122.16%	-124.04%	913.98%
Pretax Income	-$2.809M	-$2.491M	-$5.990M
YoY Change	-88.56%	-58.42%	232.78%
Income Tax	$100.0K	$100.0K	$16.35K
% Of Pretax Income
Net Earnings	-$4.016M	-$6.223M	-$6.007M
YoY Change	-83.68%	3.59%	234.02%
Net Earnings / Revenue	-182.46%	-444.51%	-125.54%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.11	-$1.74	-$2.24
COMMON SHARES
Basic Shares Outstanding	42.91M shares	42.75M shares	31.41M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.250M	$9.390M	$2.180M
YoY Change	-23.25%	330.73%	-60.07%
Cash & Equivalents	$5.251M	$9.387M	$2.180M
Short-Term Investments
Other Short-Term Assets	$1.770M	$900.0K	$960.0K
YoY Change	36.15%	-6.25%	134.15%
Inventory	$402.3K	$617.6K	$1.541M
Prepaid Expenses
Receivables	$4.960M	$2.860M	$3.310M
Other Receivables	$200.0K	$140.0K	$3.840M
Total Short-Term Assets	$12.59M	$13.90M	$11.84M
YoY Change	-31.85%	17.41%	98.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.496M	$1.526M	$58.42K
YoY Change	1524.86%	2511.99%	75.14%
Goodwill	$16.41M	$16.41M	$18.07M
YoY Change	0.0%	-9.18%
Intangibles	$26.60M	$27.63M	$32.00M
YoY Change	-18.06%	-13.66%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$150.0K	$180.0K
YoY Change	-44.44%	-16.67%	200.0%
Total Long-Term Assets	$44.60M	$45.72M	$50.31M
YoY Change	-9.23%	-9.11%	52196.25%
TOTAL ASSETS
Total Short-Term Assets	$12.59M	$13.90M	$11.84M
Total Long-Term Assets	$44.60M	$45.72M	$50.31M
Total Assets	$57.19M	$59.62M	$62.15M
YoY Change	-15.41%	-4.06%	927.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$826.5K	$1.445M	$2.940M
YoY Change	-46.19%	-50.83%	798.23%
Accrued Expenses	$12.18M	$11.19M	$9.490M
YoY Change	20.12%	17.91%	1218.06%
Deferred Revenue			$819.4K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.050M	$1.050M	$1.050M
YoY Change	0.0%	0.0%	72.81%
Total Short-Term Liabilities	$17.26M	$18.77M	$19.05M
YoY Change	-30.71%	-1.47%	1045.77%
LONG-TERM LIABILITIES
Long-Term Debt	$14.25M	$14.28M	$14.38M
YoY Change	-0.68%	-0.68%	2266.13%
Other Long-Term Liabilities	$1.121M	$1.212M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$15.38M	$15.49M	$14.38M
YoY Change	7.13%	7.75%	2266.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.26M	$18.77M	$19.05M
Total Long-Term Liabilities	$15.38M	$15.49M	$14.38M
Total Liabilities	$38.97M	$41.92M	$42.93M
YoY Change	-18.98%	-2.33%	1373.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$115.9M	-$111.9M	-$68.06M
YoY Change	25.08%	64.42%	-7.78%
Common Stock	$44.11K	$42.90K	$33.79K
YoY Change	8.49%	26.95%	139.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.22M	$17.70M	$19.22M
YoY Change
Total Liabilities & Shareholders Equity	$57.19M	$59.62M	$62.15M
YoY Change	-15.41%	-4.06%	927.58%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$4.016M	-$6.223M	-$6.007M
YoY Change	-83.68%	3.59%	234.02%
Depreciation, Depletion And Amortization	$1.070M	$1.100M	$1.240M
YoY Change	0.0%	-11.29%
Cash From Operating Activities	-$7.610M	-$6.720M	-$330.0K
YoY Change	1309.26%	1936.36%	-81.25%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$90.00K	$10.00K
YoY Change	-100.0%	800.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	-$90.00K	-$10.00K
YoY Change	-100.0%	800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.510M	90.00K	40.00K
YoY Change	-8.59%	125.0%	-99.05%
NET CHANGE
Cash From Operating Activities	-7.610M	-6.720M	-330.0K
Cash From Investing Activities	0.000	-90.00K	-10.00K
Cash From Financing Activities	3.510M	90.00K	40.00K
Net Change In Cash	-4.100M	-6.720M	-300.0K
YoY Change	-187.42%	2140.0%	-112.24%
FREE CASH FLOW
Cash From Operating Activities	-$7.610M	-$6.720M	-$330.0K
Capital Expenditures	$0.00	$90.00K	$10.00K
Free Cash Flow	-$7.610M	-$6.810M	-$340.0K
YoY Change	1212.07%	1902.94%	-80.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q2	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1132456	USD
	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	40240	USD
CY2019Q2	cerc	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	19333	USD
	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	28668	USD
CY2019Q2	cerc	Accrued Medicaid Rebates AccruedMedicaidRebates	2658184	USD
CY2018Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	278132	USD
CY2018Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	235721	USD
CY2019Q2	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	182835	USD
CY2018Q4	cerc	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	19731373	USD
CY2019Q2	cerc	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	13347741	USD
CY2018Q4	cerc	Accrued Medicaid Rebates AccruedMedicaidRebates	2237269	USD
CY2018Q4	cerc	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	3972510	USD
CY2019Q2	cerc	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	4579975	USD
	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	177238	USD
CY2018Q2	cerc	Fair Value Adjustmentof Warrants And Investor Rights Obligation And Contingent Consideration FairValueAdjustmentofWarrantsAndInvestorRightsObligationAndContingentConsideration	-3918	USD
	cerc	Fair Value Adjustmentof Warrants And Investor Rights Obligation And Contingent Consideration FairValueAdjustmentofWarrantsAndInvestorRightsObligationAndContingentConsideration	19332	USD
CY2019Q2	cerc	Fair Value Adjustmentof Warrants And Investor Rights Obligation And Contingent Consideration FairValueAdjustmentofWarrantsAndInvestorRightsObligationAndContingentConsideration	-18910	USD
	cerc	Fair Value Adjustmentof Warrants And Investor Rights Obligation And Contingent Consideration FairValueAdjustmentofWarrantsAndInvestorRightsObligationAndContingentConsideration	28668	USD
	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	class_of_stock
	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	class_of_stock
CY2019Q2	cerc	Lessee Operating Lease Liability Annual Base Rent LesseeOperatingLeaseLiabilityAnnualBaseRent	161671	USD
	cerc	Lessee Operating Lease Number Of Contracts LesseeOperatingLeaseNumberOfContracts	1	contract
	cerc	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	2	renewal_option
	cerc	Lessee Operating Lease Remaining Lease Team LesseeOperatingLeaseRemainingLeaseTeam	P10Y6M28D
	cerc	Lessee Operating Lease Rent Abatement Period LesseeOperatingLeaseRentAbatementPeriod	P12M
CY2018Q4	cerc	License Obligation Noncurrent LicenseObligationNoncurrent	1250000	USD
CY2019Q2	cerc	License Obligation Noncurrent LicenseObligationNoncurrent	1250000	USD
CY2018Q4	cerc	Minimum Sales Commitments Royalties Payable And Purchase Obligations Current MinimumSalesCommitmentsRoyaltiesPayableAndPurchaseObligationsCurrent	9662901	USD
CY2019Q2	cerc	Minimum Sales Commitments Royalties Payable And Purchase Obligations Current MinimumSalesCommitmentsRoyaltiesPayableAndPurchaseObligationsCurrent	2154613	USD
CY2018Q2	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	-5991125	USD
	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	-9850655	USD
CY2019Q2	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	-6156682	USD
	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	-13444371	USD
CY2019Q2	cerc	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	class_of_stock
	cerc	Number Of Redemption Or Sinking Fund Provisions NumberOfRedemptionOrSinkingFundProvisions	0	class_of_stock
	cerc	Operating Leases Rent Expense Annual Increase Percent OperatingLeasesRentExpenseAnnualIncreasePercent	0.025
CY2017Q3	cerc	Potential Future Regulatory Milestone PotentialFutureRegulatoryMilestone	20000000	USD
	cerc	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	390473	USD
	cerc	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	256816	USD
	cerc	Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent	0.04
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2018Q2	cerc	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	27082	USD
	cerc	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	390473	USD
CY2019Q2	cerc	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	162639	USD
	cerc	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	256816	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42906744	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Registrant Name EntityRegistrantName	Cerecor Inc.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1446141	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1445475	USD
CY2018Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	5469011	USD
CY2019Q2	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	143011	USD
CY2018Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3157555	USD
CY2019Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	2860288	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2032258	USD
CY2019Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1392474	USD
CY2018Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	19731373	USD
CY2019Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13347741	USD
CY2018Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1112378	USD
CY2019Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	627025	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119082157	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129545721	USD
CY2019Q2	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-18057	USD
	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-18057	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	608431	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	851255	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	526709	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1123402	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	608431	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	851255	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	526709	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1123402	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1233035	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2250444	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1078847	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2157694	USD
CY2018Q4	us-gaap	Assets Assets	70250721	USD
CY2019Q2	us-gaap	Assets Assets	59620884	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	21931893	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	13899100	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	276008	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-811948	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1956807	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1529386	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7093757	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	6329975	USD
CY2018Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	15075000	USD
CY2019Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	0	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2179775	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10646301	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9386865	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9400000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2605499	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2364344	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10746756	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9565292	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-241155	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1181464	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.50
CY2018Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4000000	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40804189	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42898251	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40804189	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42898251	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	40804	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	42898	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1422957	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2286582	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	-141822	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1806070	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	23764	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	18870	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	69238	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	88108	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2262570	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2203423	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1953065	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1974655	USD
CY2017Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2017Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2019Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2018Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-13239	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-276008	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	373299	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	992350	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	811948	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3041955	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5949318	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2382007	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5098990	USD
CY2018Q4	us-gaap	Goodwill Goodwill	16411123	USD
CY2019Q2	us-gaap	Goodwill Goodwill	16411123	USD
CY2018Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1701875	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1701875	USD
CY2019Q2	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1449121	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1449121	USD
CY2018Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1900000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	16351	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39664	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66417	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	232776	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	852025	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1640959	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-666	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-297267	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-88100	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-639784	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	5287	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	617619	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-452931	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2397968	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-6313686	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-339221	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-5326000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-318771	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-664454	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31239468	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27632653	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-242407	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-342810	USD
CY2019Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-199746	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-407685	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	525000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	1110780	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	617609	USD
CY2019Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.077
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1860455	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	27859608	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1183290	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	178092	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	173748	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	169510	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	155815	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	0	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	648187	USD
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2018Q4	us-gaap	Liabilities Liabilities	49342973	USD
CY2019Q2	us-gaap	Liabilities Liabilities	41924625	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70250721	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59620884	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26216579	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	18765076	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1050000	USD
CY2019Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1050000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14327882	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14279198	USD
CY2017Q4	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.10
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	398873	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8914317	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25932	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-256926	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-614096	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9838855	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9800000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-6007476	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9890319	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-6223099	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13700000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13677147	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-238489	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-343488	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-180836	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-445753	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	10537774	USD
	us-gaap	Operating Expenses OperatingExpenses	18775080	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	10425250	USD
	us-gaap	Operating Expenses OperatingExpenses	22859465	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5752636	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9507167	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5975846	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12998618	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	39534	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	94140	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25931	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1212268	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1212268	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	728138	USD
CY2018Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	49241	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	96800	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	279397	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	37998	USD
CY2018Q2	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	18654	USD
CY2019Q2	us-gaap	Other Income OtherIncome	0	USD
	us-gaap	Other Income OtherIncome	-9400	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	385517	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1212268	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	351566	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	379255	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	18057	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	256926	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2857143	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2857143	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2857143	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2857143	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	2857	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	2857	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1529516	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	865062	USD
CY2018Q2	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	13239	USD
	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	276008	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8975960	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	8400	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	127537	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	586512	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1525846	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	48684	USD
CY2018Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1082698	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2732475	USD
CY2019Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3712596	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7113785	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9527	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	18730	USD
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	26265	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	175042	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	81725	USD
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	152162	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98218070	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111895217	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111900000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4785000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4785138	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9268000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9267913	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4449404	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4449000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9860847	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9861000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	743025	USD
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	363637	shares
CY2019Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.50
CY2018Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2042015	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3578378	USD
CY2019Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2936851	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6045753	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	851255	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1123402	USD
CY2019Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	3723	shares
	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	3723	shares
CY2019Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	61250	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	161250	shares
CY2018Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	8400	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	8400	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	127537	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	127537	USD
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8975960	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	24582980	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	19219417	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	20907748	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	23120530	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	17696259	USD
CY2018Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y6M
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Business</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cerecor Inc. (the Company or “Cerecor”) is a fully integrated biopharmaceutical company with commercial operations and research and development capabilities. The Company is building a pipeline of innovative therapies in orphan diseases, neurology and pediatric healthcare. The Company's pediatric orphan disease pipeline is led by CERC-801, CERC-802 and CERC-803. All </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> compounds are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation ("CDGs") by means of substrate replacement therapy. The U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease Designation ("RPDD") and Orphan Drug Designation ("ODD") to all </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> CERC-800 compounds, thus qualifying the Company to receive a Priority Review Voucher ("PRV") upon approval of a new drug application ("NDA"). The PRV may be sold or transferred an unlimited number of times. The Company plans to leverage the 505(b)(2) NDA pathway for all </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> compounds to accelerate development and approval. The Company is also in the process of developing </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> other preclinical pediatric orphan rare disease compound, CERC-913, for the treatment of mitochondrial DNA Depletion Syndrome. The Company's neurology pipeline is led by CERC-301, a Glutamate NR2B selective, NMDA Receptor antagonist, which Cerecor is currently developing as a novel treatment for orthostatic hypotension ("OH"). The Company is also developing CERC-406, a CNS-targeted COMT inhibitor for Parkinson's Disease. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also has a diverse portfolio of marketed products. Our marketed products are led by our prescribed dietary supplements and prescribed drugs. Our prescribed dietary supplements include Poly-Vi-Flor® and Tri-Vi-Flor™ which are prescription vitamin and fluoride supplements used in infants and children to treat or prevent deficiency of essential vitamins and fluoride. The Company also markets a number of prescription drugs that treat a range of pediatric diseases, disorders and conditions. Cerecor's prescription drugs include Millipred®, Karbinal™ ER, AcipHex® Sprinkle™ and Cefaclor for Oral Suspension. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cerecor was incorporated in 2011 and commenced operations in 2011 and completed an initial public offering in October 2015. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 17, 2017, the Company acquired TRx Pharmaceuticals, LLC (“TRx”) and its wholly-owned subsidiaries (see "TRx Acquisition" in </font><font style="font-family:inherit;font-size:10pt;">Note 5</font><font style="font-family:inherit;font-size:10pt;"> below for a description of this transaction).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2018, Cerecor acquired all rights to Avadel Pharmaceuticals PLC’s (“Avadel”) marketed pediatric products (the “Acquired Products”) in exchange for Cerecor assuming certain financial obligations of Avadel (see "Avadel Pediatric Products Acquisition" in </font><font style="font-family:inherit;font-size:10pt;">Note 5</font><font style="font-family:inherit;font-size:10pt;"> below for a description of this transaction).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 25, 2018, the Company acquired Ichorion Therapeutics, Inc., a privately-held biopharmaceutical company focused on developing treatments and increasing awareness of inherited metabolic disorders known as CDGs (see "Ichorion Asset Acquisition" in Note 5 below for a description of this transaction).</font></div><div style="line-height:120%;text-align:justify;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company's resources between investing in the Company's current commercial product line, the Company's development portfolio and acquisitions or in-licensing of new assets. For the six months ended June 30, 2019, Cerecor generated a net loss of </font><font style="font-family:inherit;font-size:10pt;">$13.7 million</font><font style="font-family:inherit;font-size:10pt;"> and negative cash flow from operations of </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">.  As of June 30, 2019, Cerecor had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$111.9 million</font><font style="font-family:inherit;font-size:10pt;"> and a balance of </font><font style="font-family:inherit;font-size:10pt;">$9.4 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents. During the first quarter of 2019, the Company closed an underwritten public offering of common stock for </font><font style="font-family:inherit;font-size:10pt;">1,818,182</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of the Company, at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$5.50</font><font style="font-family:inherit;font-size:10pt;"> per share ("public price"). Armistice Capital Master Fund Ltd. ("Armistice"), our largest stockholder, participated in the offering by purchasing </font><font style="font-family:inherit;font-size:10pt;">363,637</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of the Company from the underwriter at the public price. Cerecor director Steven J. Boyd is Armistice's Chief Investment Officer. The net proceeds of the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;"> (see "Common Stock Offering" in Note 9 below for description of the transaction). </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company plans to use cash and the anticipated cash flows from the Company's existing product sales to offset costs related to its neurology programs, pediatric rare disease programs, business development, costs associated with its organizational infrastructure, and debt principal and interest payments. Cerecor expects to continue to incur significant expenses and operating losses for the immediate future as it continues to invest in the Company's pipeline assets. Our ability to achieve and maintain profitability in the future is dependent on, among other things, the development, regulatory approval, and commercialization of our new product candidates and achieving a level of revenues from our existing product sales adequate to support our cost structure, which includes significant investment in our pipeline assets. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes it will require additional financing to continue to execute its clinical development strategy and fund future operations. The Company plans to meet its capital requirements through operating cash flows from product sales and some combination of equity or debt financings, collaborations, out-licensing arrangements, strategic alliances, federal and private grants, marketing, distribution or licensing arrangements or the sale of current or future assets. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible or suspend or curtail planned programs. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our plan to aggressively develop our pipeline will require substantial cash in excess of what the Company expects our current commercial operations to generate.  However, the Company expects that our existing cash and cash equivalents, together with anticipated revenue, will enable us to fund our operating expenses, capital expenditure requirements, and other non-operating cash payments, such as fixed quarterly payments on our outstanding debt balances, through at least August 2020.</font></div></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassification</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2018, the Company concluded that going forward it would include change in fair value of contingent consideration within its own stand-alone line in operating expenses in the Company's statements of operations. The Company has reclassified </font><font style="font-family:inherit;font-size:10pt;">$13,239</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$276,008</font><font style="font-family:inherit;font-size:10pt;"> from other expenses to operating expenses in the three and six months ended June 30, 2018, respectively, on the statement of operations to conform with current period presentation. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0001628280-19-010465-index-headers.html	Edgar Link	pending
0001628280-19-010465-index.html	Edgar Link	pending
0001628280-19-010465.txt	Edgar Link	pending
0001628280-19-010465-xbrl.zip	Edgar Link	pending
cerc-20190630.xml	Edgar Link	completed
cerc-20190630.xsd	Edgar Link	pending
cerc-20190630_cal.xml	Edgar Link	unprocessable
cerc-20190630_def.xml	Edgar Link	unprocessable
cerc-20190630_lab.xml	Edgar Link	unprocessable
cerc-20190630_pre.xml	Edgar Link	unprocessable
cerc10-q20190630.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
productpipelineassetchart811.jpg	Edgar Link	pending
q22019cercex-311.htm	Edgar Link	pending
q22019cercex-321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rdupcomingmilestonechart8119.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2019 Q3 Form 10-Q Financial Statement

#000162828019010465 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2019 Q3 Form 10-Q Financial Statement

#000162828019010465 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx